Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

ial with positive results.

"We believe the latest encouraging results with LX4211 demonstrate the potential for a therapeutic benefit for patients with type 2 diabetes," said Dr. Arthur T. Sands, president and CEO of Lexicon.  "With positive results within the last few months from Phase 2 clinical trials of two candidates, we are proceeding with confidence that our drug discovery platform has produced investigational new drugs with great promise for patients."

For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

About the LX4211 Mechanism of Action

LX4211 was developed at Lexicon as a potent inhibitor of the sodium glucose cotransporter 2 (SGLT2), a transporter responsible for the majority of glucose reabsorption by the kidneys.  Lexicon found that mouse knockouts engineered to lack the SGLT2 gene are healthy and require less insulin to manage a glucose challenge.  LX4211 may potentially treat diabetes by improving glycemic control as well as providing other metabolic benefits.

About Diabetes

Diabetes mellitus is a common metabolic disorder associated with abnormally high blood sugar levels.  Diabetes is classified as either type 1, which is characterized by severely diminished insulin production, or type 2, which is characterized by moderately diminished insulin production in conjunction with insulin resistance (insensitivity of the tissues of the body to insulin).
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, ... healthcare products, announced today that the company is ... "We are pleased to sponsor Operation Troop ... Chairman of PuraMed BioScience. "Research shows that many ... migraines much more frequently than the general population. ...
(Date:7/22/2014)... -- Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: ... the Icahn School of Medicine at Mount ... to utilize its proprietary information and data package for ... Type C Disease (NPC), a rare disease, mostly of ... also covers other diseases and disorders relying on activation ...
(Date:7/22/2014)... -- According to the American Optometric Association (AOA), parents severely ... An AOA survey reports that 83 percent of children ... use an electronic device for three or more hours ... revealed that only 40 percent of parents believe their ... of time. Eye doctors are concerned that this significant ...
Breaking Medicine Technology:PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4
... Colo., May 13, 2011 Mesa Laboratories, Inc. (NASDAQ: ... of Directors has declared a regular quarterly cash dividend ... on June 15, 2011 to shareholders of record at ... Mesa Laboratories develops, acquires, manufactures and markets electronic ...
... Cookeville-based Aphena Pharma Solutions Inc., a leading pharmaceutical ... that on June 1, Mary G. Foster, PharmD — one ... join the company as its Corp. VP of Quality and ... shape its vision, plan long-term goals, and further enhance the ...
Cached Medicine Technology:Top Industry Professional Joins Aphena as Head of Quality & Regulatory Affairs 2
(Date:7/22/2014)... July 22, 2014 The Restful Jaw ... the Restful Jaw ®. The FDA-registered external device ... while minimizing jaw pain, fatigue and soreness during dental ... treatment times when patients do not need to take ... The Restful Jaw is a vital solution in helping ...
(Date:7/22/2014)... University of the Pacific's Arthur A. ... of its state-of-the-art, $151 million campus this month. The ... San Francisco's South of Market (SoMa) district and houses ... patients will now be greeted by a wall of ... , Advanced Kiosks engineering team designed custom software to ...
(Date:7/22/2014)... HealthDay Reporter , MONDAY, July 21, 2014 (HealthDay ... high school may take fewer health risks than their peers ... of low-income Los Angeles teens, found that those who attended ... binge-drink, have multiple sex partners or take certain other health ... kids" being more likely to go to good schools, researchers ...
(Date:7/22/2014)... 21, 2014) Investigators at the Cedars-Sinai Samuel ... multistep investigational treatment for one of the most ... advanced pancreatic cancer. , Locally advanced pancreatic ... solid tumor, with a cumulative five-year survival rate ... disease. Surgery is rarely an option for patients ...
(Date:7/22/2014)... like electroconvulsive therapy (ECT) and transcranial magnetic stimulation ... depression. Like antidepressant medications, however, they typically have ... receive several weeks of regular ECT treatments before ... is an impetus to develop antidepressant treatments that ... stimulation (LFMS) is one such potential new treatment ...
Breaking Medicine News(10 mins):Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:iKiosks Are Gateway to Premier Dental Facility 2Health News:iKiosks Are Gateway to Premier Dental Facility 3Health News:Good Schools May Be Good for a Teen's Health, Too 2Health News:Good Schools May Be Good for a Teen's Health, Too 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3Health News:Low strength brain stimulation may be effective for depression 2
... areas of B.C. are up to twice as likely ... better-off areas, a University of British Columbia study has ... online journal Public Library of Science ONE , ... are more vulnerable to death from chronic disease, particularly ...
... N.Y., Jan. 8 Davis Vision, Inc., headquartered in ... of sales for its Northern division. In this new ... Davis Vision,s national new business development. "Mike will be ... said Tom Davis, Davis Vision,s executive vice president and ...
... Supplement Health and Education Act Mandates Label ... , WASHINGTON, Jan. 8 In response ... supplement regulation, the Natural Products Association,s Executive ... statement:Increased scrutiny by professional sports leagues on ...
... illness can lead to poorer quality of lifeparticularly ... help teens cope with their conditions. , Two ... professor of medicine, and Sian Cotton, PhD, research ... investigated how adolescents with inflammatory bowel disease (IBD)a ...
... on pets during National Glaucoma month. , ... Tampa, ... Month, Florida Veterinary Specialists (FVS) are spreading the word ... as humans.    , , ,"When eyes go bad, they often do so ...
... much more likely to be deadly for women and African-Americans, ... for only part of the differences for such patients compared ... in the Jan. 1 issue of the journal Cancer ... If age, tumor type, and stage of the disease upon ...
Cached Medicine News:Health News:Mortality rates higher for heart disease patients in poorer B.C. neighborhoods 2Health News:Davis Vision, Inc. Names Michael Ehrle Divisional Vice President of Sales 2Health News:Natural Products Association Advocates Strength of Dietary Supplement Law 2Health News:Spirituality may help adolescents cope with chronic illness 2Health News:Spirituality may help adolescents cope with chronic illness 3Health News:Glaucoma Awareness Not Just for Humans 2Health News:Glaucoma Awareness Not Just for Humans 3Health News:Why Bladder Cancer Is Deadlier for Some 2Health News:Why Bladder Cancer Is Deadlier for Some 3Health News:Why Bladder Cancer Is Deadlier for Some 4
MicroAmp Full Plate Covers, which are manufactured from PCR-compatible rubber, are non-sterile, autoclavable and guaranteed reusable up to five times....
96-Well PCR Plate Sealing Mat...
Inquire...
Inquire...
Medicine Products: